{"filing":{"accession_number":"0001345099-26-000062","cik":"0001345099","ticker":"MEOBF","company_name":"MESOBLAST LTD","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"form6-kxpressreleasecoverf.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509926000062/form6-kxpressreleasecoverf.htm"},"events":[{"id":15203,"run_id":13570,"accession_number":"0001345099-26-000062","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Mesoblast announced receipt of a BLA filing number from the FDA and requested modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. This represents a material regulatory milestone in the clinical development pathway—the formal submission of a biologics license application to the FDA—which is a significant operational and strategic event for a biopharmaceutical company. While not a discrete event type like M\u0026A or exec change, this regulatory filing milestone materially advances the company's product development program and would affect investor assessment of near-term regulatory prospects.","company_name":"MESOBLAST LTD","ticker":"MEOBF","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12888,"accession_number":"0001345099-26-000062","item_number":"EX-99.1","item_title":"exhibit991lvadblasubmiss.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Mesoblast announced receipt of a BLA filing number from the FDA and requested modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. This represents a material regulatory milestone in the clinical development pathway—the formal submission of a biologics license application to the FDA—which is a significant operational and strategic event for a biopharmaceutical company. While not a discrete event type like M\u0026A or exec change, this regulatory filing milestone materially advances the company's product development program and would affect investor assessment of near-term regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:24:30.944107+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12888,"accession_number":"0001345099-26-000062","item_number":"EX-99.1","item_title":"exhibit991lvadblasubmiss.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Mesoblast announced receipt of a BLA filing number from the FDA and requested modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. This represents a material regulatory milestone in the clinical development pathway—the formal submission of a biologics license application to the FDA—which is a significant operational and strategic event for a biopharmaceutical company. While not a discrete event type like M\u0026A or exec change, this regulatory filing milestone materially advances the company's product development program and would affect investor assessment of near-term regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:24:30.944107+00:00","company_name":"MESOBLAST LTD","ticker":"MEOBF","filing_date":"2026-06-30"}]}